Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Camptothecin | HCID 24360 | — |
| Catalyst | Platinum oxide (PtO) | HCID 82844 | — |
| Solvent | Acetic Acid | HCID 176 | — |
| Product | HCID 11024585 | HCID 11024585 | 76.7% |
Reaction Steps
Camptothecin (500 mg, 1.43 m-mol) is suspended in acetic acid (100 ml). Platinum oxide (100 mg) is added to the suspension and the mixture is subjected to catalytic reduction (1.5 hours, absorption of about 140 ml of hydrogen) at room temperature under atmospheric pressure. After removing the catalyst by filtration, the reaction mixture is evaporated until dryness under reduced pressure. The residue is taken up in chloroform (200 ml) and washed with a 5% aqueous solution of sodium hydrogen carbonate (100 ml) and then with a saturated solution of edible salt (100 ml). The chloroform phase is dried over magnesium sulfate, filtered and evaporated under reduced pressure until dryness. The residue is purified by column chromatography (chloroform) on silica gel (20 g) whereby 285 mg (conversion rate: 56.3%; yield: 76.7%) of the title compound is obtained as yellowish white crystals. Unreacted starting material (113 mg in crude state) is recovered. M.P. (dec.) 240°-242° C. (from methanol)
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04545880 |
|---|
| Source dataset | uspto-grants-1985_10 |
|---|
| ORD ID | ord-46f551b40c694d55ad11da5a7998136e |
|---|
| Source note | uspto-grants-1985_10 |
|---|